Texas will receive $1 million as part of a multi-state settlement with the New York based pharmaceutical giant Bristol-Myers Squibb for improper marketing of its anti-psychotic drug Abilify. Without regulatory approval, Bristol-Myers Squibb promoted Ailify to treat elderly patients with dementia but did not disclose dementia patients faced a greater risk of death.